Skip to content

Study on the safety and efficacy of Remazolam toluenesulfonic acid in painless induced abortion

Study on the safety and efficacy of Remazolam toluenesulfonic acid in painless induced abortion

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037526
Enrollment
Unknown
Registered
2020-08-29
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless induced abortion

Interventions

Sponsors

Jingzhou First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. The subjects with accurate and complete clinical data; 2. Aged 18 to 46 years, ASA grade I-II, BMI 18-28 kg / m2; 3. No patients with liver and kidney dysfunction, shock and cardiopulmonary dysfunction; 4. Those who have the ability of reading and understanding; have the knowledge of this research and participate voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients with obvious respiratory and circulatory dysfunction, abnormal blood routine and blood biochemical indexes before operation; 2. Patients with severe neuropsychiatric diseases; 3. Patients with infectious diseases; 4. Patients who took benzodiazepines or opioids every day or in recent 3 months within 1 month; 5. Patients who are allergic or contraindicated to benzodiazepines, opioids, propofol, flumazenil, naloxone and other drugs; 6. Patients with respiratory tract management difficulties: modified Markovian score grade III and above.

Design outcomes

Primary

MeasureTime frame
HR, RR, SPO2, NBP and BIS of the subjects after starting administration until the end of operation were stable, and the continuous change trend (diachronic change) was recorded.;MOAA/S score during operation;The time from the end of the last dose until the subject is fully awake;The standard time for subjects to leave the hospital after the operation;Incidence of injection pain;

Countries

China

Contacts

Public ContactRui Xia

Jingzhou First People's Hospital

879560350@qq.com+86 18972161338

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026